Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
US11279703B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2017 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Dec 15, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to fused pyrimidine compounds, particularly pyrrolopyrimidine and thienopyrimidine compounds and derivatives thereof, pharmaceutical compositions thereof, and methods of inhibiting BRD4 and/or JAK2, as well as methods of treating various diseases and conditions, such as cancer and leukemia, with such compounds. Bromodomain binding and JAK activity are included.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.